revenue guidance

CorMedix (CRMD) Q3 2025: Net Income Hits $108.6M, FY25 Guidance Raised to $390–$410M — Nov 12, 2025

CorMedix Inc. (NASDAQ: CRMD) reported a profitable third quarter and lifted full‑year guidance today as momentum in DefenCath and contributions from the Melinta portfolio accelerated growth. TradingView What happened CorMedix said third‑quarter 2025 net revenue came in at $104.3 million

12 November 2025

Conduent Stock Plunges 24% After Q3 Miss and Revenue Guidance Cut—Analysts Still See Upside (Nov. 10, 2025)

Conduent (CNDT) shares are in focus after a brutal post‑earnings slide. Coverage today highlights a roughly 24–25% drop tied to a weaker‑than‑expected Q3 and a cut to full‑year 2025 revenue guidance, deepening investor concerns about the turnaround. Yahoo Finance Key

10 November 2025

Company Performance · Earnings Reports · Financial News · Investment Analysis · NYSE:CNDT · Stock Market